Form 4: Janux Therapeutics Chief Business Officer Exercises Stock Options
SEC Form 4 Filing
Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, exercised stock options on December 19, 2024, acquiring 9,881 shares of common stock.
Summary
- Andrew Hollman Meyer, the Chief Business Officer of Janux Therapeutics, exercised stock options on December 19, 2024.
- He acquired 9,880 shares of common stock at a price of $20.24 per share and 1 share at a price of $14.02 per share.
- These transactions increased his direct holdings of common stock to 77,473 shares.
- The exercised options were part of previously granted stock option plans with vesting schedules.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation, which is generally neutral to positive. The exercise of options indicates confidence in the company's future.
Industry Context
This is a routine filing related to executive compensation and is common in publicly traded companies. It reflects the vesting and exercise of stock options granted to company executives.
Comparison to Industry Standards
- Stock option grants and exercises are a standard form of compensation for executives in the biotechnology industry.
- The vesting schedules described are typical, with a portion vesting initially and the remainder vesting over a period of years.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it increases the number of outstanding shares, but it is a standard part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 12/19/2024 | Date of stock option exercise by Andrew Hollman Meyer. |
| 12/20/2024 | Date of signature on the SEC Form 4 filing. |
| 01/01/2023 | Date when 25% of the first stock option grant vested. |
| 01/02/2032 | Expiration date of the first stock option grant. |
| 01/01/2024 | Date when 25% of the second stock option grant vested. |
| 01/02/2033 | Expiration date of the second stock option grant. |
Keywords
stock options, insider trading, Janux Therapeutics, equity, SEC Form 4, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.